Eton Pharmaceuticals Inc. (ETON)
Company Description
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.
The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis.
In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector.
Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Country | United States |
IPO Date | Nov 13, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 31 |
CEO | Sean E. Brynjelsen |
Contact Details
Address: 21925 West Field Parkway Deer Park, Illinois United States | |
Website | https://www.etonpharma.com |
Stock Details
Ticker Symbol | ETON |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001710340 |
CUSIP Number | 29772L108 |
ISIN Number | US29772L1089 |
Employer ID | 37-1858472 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Sean E. Brynjelsen | President, Chief Executive Officer & Director |
James R. Gruber CPA | Chief Financial Officer, Treasurer & Secretary |
Danka Radosavljevic | Senior Vice President of Quality & Operations |
David C. Krempa | Chief Business Officer |
Ipek Erdogan-Trinkaus | Chief Commercial Officer |
Kevin Guthrie | Executive Vice President of Commercial Operations |
Scott Grossenbach | Senior Vice President of Sales Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 18, 2025 | 8-K | Current Report |
Mar 18, 2025 | 8-K | Current Report |
Mar 18, 2025 | 10-K | Annual Report |
Mar 14, 2025 | 8-K | Current Report |
Mar 07, 2025 | 8-K/A | [Amend] Current Report |
Mar 03, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 07, 2025 | 8-K | Current Report |
Feb 06, 2025 | 8-K | Current Report |
Jan 06, 2025 | 4 | Filing |